<DOC>
	<DOCNO>NCT02165774</DOCNO>
	<brief_summary>Prospective , randomize , placebo-controlled , double-blind multicenter trial include 4 tertiary sacral neuromodulation referral center Switzerland ( ZÃ¼rich , Bern , Nottwil , St.Gallen ) . Patients refractory neurogenic LUTD include randomized neuromodulator implantation sacral neuromodulation ON sacral neuromodulation OFF ( n=30 ) 2 month double-blind phase . In addition standard neuro-urological assessment , patient agree also undergo neurophysiological investigation lower urinary tract , i.e . record current perception threshold , sensory evoked potential , electroencephalography stimulation urethra bladder .</brief_summary>
	<brief_title>Sacral Neuromodulation Neurogenic LUT Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Neurotransmitter Agents</mesh_term>
	<criteria>Refractory neurogenic LUTD Urgency frequency syndrome and/or urgency incontinence refractory antimuscarinics ( pharmacotherapy least 4 week least 2 antimuscarinics ) Chronic urinary retention refractory alphablocker ( pharmacotherapy alphablocker least 4 week ) Combination urgency frequency syndrome and/or urgency incontinence chronic urinary retention refractory antimuscarinics ( pharmacotherapy least 4 week least 2 antimuscarinics ) alphablocker ( pharmacotherapy alphablocker least 4 week ) Stable neurological disease/injury least 12 month Age minimum 18 year Informed consent Botulinum A toxin injection detrusor and/or urethral sphincter last 6 month Age 18 year Pregnancy Individuals especially need protection ( accord Research Human Subjects publish Swiss Academy Medical Sciences ) No informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>sacral neuromodulation , neurogenic low urinary tract dysfunction</keyword>
</DOC>